{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:18:22Z","timestamp":1778869102453,"version":"3.51.4"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82474011"],"award-info":[{"award-number":["82474011"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ40802"],"award-info":[{"award-number":["2023JJ40802"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019092","name":"Science Fund for Distinguished Young Scholars of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ40802"],"award-info":[{"award-number":["2023JJ40802"]}],"id":[{"id":"10.13039\/501100019092","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012476","name":"Fundamental Research Funds for Central Universities of the Central South University","doi-asserted-by":"publisher","award":["2025ZZTS0153"],"award-info":[{"award-number":["2025ZZTS0153"]}],"id":[{"id":"10.13039\/501100012476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s11095-026-04043-1","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T23:59:21Z","timestamp":1771977561000},"page":"1101-1112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimating Human Jejunal Effective Permeability Using Numerical Deconvolution of Oral Solution Concentration Data"],"prefix":"10.1007","volume":"43","author":[{"given":"Wenqian","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Geng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingrui","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanxi","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9038-2676","authenticated-orcid":false,"given":"Feifan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"3","key":"4043_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1211\/0022357055263","volume":"57","author":"H Lennern\u00e4s","year":"2005","unstructured":"Lennern\u00e4s H, Abrahamsson B. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol. 2005;57(3):273\u201385. https:\/\/doi.org\/10.1211\/0022357055263.","journal-title":"J Pharm Pharmacol"},{"issue":"5","key":"4043_CR2","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/0009-9236(95)90168-x","volume":"58","author":"CY Wu","year":"1995","unstructured":"Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther. 1995;58(5):492\u20137. https:\/\/doi.org\/10.1016\/0009-9236(95)90168-x.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"4043_CR3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/a:1016212804288","volume":"12","author":"GL Amidon","year":"1995","unstructured":"Amidon GL, Lennern\u00e4s H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413\u201320. https:\/\/doi.org\/10.1023\/a:1016212804288.","journal-title":"Pharm Res"},{"key":"4043_CR4","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ejps.2013.09.008","volume":"57","author":"ES Kostewicz","year":"2014","unstructured":"Kostewicz ES, Aarons L, Bergstrand M, Bolger MB, Galetin A, Hatley O, et al. PBPK models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci. 2014;57:300\u201321. https:\/\/doi.org\/10.1016\/j.ejps.2013.09.008.","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"4043_CR5","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1002\/jps.24258","volume":"104","author":"D Dahlgren","year":"2015","unstructured":"Dahlgren D, Roos C, Sj\u00f6gren E, Lennern\u00e4s H. Direct in vivo human intestinal permeability (Peff ) determined with different clinical perfusion and intubation methods. J Pharm Sci. 2015;104(9):2702\u201326. https:\/\/doi.org\/10.1002\/jps.24258.","journal-title":"J Pharm Sci"},{"issue":"10-11","key":"4043_CR6","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1080\/00498250701704819","volume":"37","author":"H Lennern\u00e4s","year":"2007","unstructured":"Lennern\u00e4s H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica. 2007;37(10\u201311):1015\u201351. https:\/\/doi.org\/10.1080\/00498250701704819.","journal-title":"Xenobiotica"},{"issue":"3","key":"4043_CR7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1136\/gut.12.3.184","volume":"12","author":"R Modigliani","year":"1971","unstructured":"Modigliani R, Bernier JJ. Absorption of glucose, sodium, and water by the human jejunum studied by intestinal perfusion with a proximal occluding balloon and at variable flow rates. Gut. 1971;12(3):184\u201393. https:\/\/doi.org\/10.1136\/gut.12.3.184.","journal-title":"Gut"},{"issue":"10","key":"4043_CR8","first-page":"1278","volume":"84","author":"L Knutson","year":"1989","unstructured":"Knutson L, Odlind B, H\u00e4llgren R. A new technique for segmental jejunal perfusion in man. Am J Gastroenterol. 1989;84(10):1278\u201384.","journal-title":"Am J Gastroenterol"},{"key":"4043_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/2050-6511-14-34","volume":"14","author":"DG Levitt","year":"2013","unstructured":"Levitt DG. Quantitation of small intestinal permeability during normal human drug absorption. BMC Pharmacol Toxicol. 2013;14:34. https:\/\/doi.org\/10.1186\/2050-6511-14-34.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"6","key":"4043_CR10","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1021\/mp500834v","volume":"12","author":"E Sj\u00f6gren","year":"2015","unstructured":"Sj\u00f6gren E, Dahlgren D, Roos C, Lennern\u00e4s H. Human in vivo regional intestinal permeability: quantitation using site-specific drug absorption data. Mol Pharm. 2015;12(6):2026\u201339. https:\/\/doi.org\/10.1021\/mp500834v.","journal-title":"Mol Pharm"},{"issue":"1","key":"4043_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1021\/mp800145r","volume":"6","author":"T Knutson","year":"2009","unstructured":"Knutson T, Fridblom P, Ahlstr\u00f6m H, Magnusson A, Tannergren C, Lennern\u00e4s H. Increased understanding of intestinal drug permeability determined by the LOC-I-GUT approach using multislice computed tomography. Mol Pharm. 2009;6(1):2\u201310. https:\/\/doi.org\/10.1021\/mp800145r.","journal-title":"Mol Pharm"},{"issue":"9","key":"4043_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.2165\/00003088-200746090-00005","volume":"46","author":"S Igel","year":"2007","unstructured":"Igel S, Drescher S, M\u00fcrdter T, Hofmann U, Heinkele G, Tegude H, et al. Increased absorption of digoxin from the human jejunum due to inhibition of intestinal transporter-mediated efflux. Clin Pharmacokinet. 2007;46(9):777\u201385. https:\/\/doi.org\/10.2165\/00003088-200746090-00005.","journal-title":"Clin Pharmacokinet"},{"key":"4043_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1985.tb02749.x","author":"G Jobin","year":"1985","unstructured":"Jobin G, Cortot A, Godbillon J, Duval M, Schoeller JP, Hirtz J, et al. Investigation of drug absorption from the gastrointestinal tract of man. I. Metoprolol in the stomach, duodenum and jejunum. Br J Clin Pharmacol. 1985. https:\/\/doi.org\/10.1111\/j.1365-2125.1985.tb02749.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"4043_CR14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3109\/10611869509015945","volume":"3","author":"U Fagerholm","year":"1995","unstructured":"Fagerholm U, Borgstr\u00f6m L, Ahrenstedt O, Lennern\u00e4s H. The lack of effect of induced net fluid absorption on the in vivo permeability of terbutaline in the human jejunum. J Drug Target. 1995;3(3):191\u2013200. https:\/\/doi.org\/10.3109\/10611869509015945.","journal-title":"J Drug Target"},{"issue":"3","key":"4043_CR15","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","volume":"59","author":"LJ McCreight","year":"2016","unstructured":"McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426\u201335. https:\/\/doi.org\/10.1007\/s00125-015-3844-9.","journal-title":"Diabetologia"},{"issue":"3","key":"4043_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1365-2125.1987.tb03178.x","volume":"24","author":"J Godbillon","year":"1987","unstructured":"Godbillon J, Vidon N, Palma R, Pfeiffer A, Franchisseur C, Bovet M, et al. Jejunal and ileal absorption of oxprenolol in man: influence of nutrients and digestive secretions on jejunal absorption and systemic availability. Br J Clin Pharmacol. 1987;24(3):335\u201341. https:\/\/doi.org\/10.1111\/j.1365-2125.1987.tb03178.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"4043_CR17","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1023\/a:1011020025338","volume":"18","author":"N Takamatsu","year":"2001","unstructured":"Takamatsu N, Kim ON, Welage LS, Idkaidek NM, Hayashi Y, Barnett J, et al. Human jejunal permeability of two polar drugs: cimetidine and ranitidine. Pharm Res. 2001;18(6):742\u20134. https:\/\/doi.org\/10.1023\/a:1011020025338.","journal-title":"Pharm Res"},{"issue":"11","key":"4043_CR18","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/j.2042-7158.1986.tb04501.x","volume":"38","author":"AE Merfeld","year":"1986","unstructured":"Merfeld AE, Mlodozeniec AR, Cortese MA, Rhodes JB, Dressman JB, Admidon GL. The effect of pH and concentration on alpha-methyldopa absorption in man. J Pharm Pharmacol. 1986;38(11):815\u201322. https:\/\/doi.org\/10.1111\/j.2042-7158.1986.tb04501.x.","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"4043_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/bf00192558","volume":"46","author":"T Gramatt\u00e9","year":"1994","unstructured":"Gramatt\u00e9 T, el Desoky E, Klotz U. Site-dependent small intestinal absorption of ranitidine. Eur J Clin Pharmacol. 1994;46(3):253\u20139. https:\/\/doi.org\/10.1007\/bf00192558.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"4043_CR20","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/j.1365-2125.1994.tb04312.x","volume":"37","author":"T Gramatt\u00e9","year":"1994","unstructured":"Gramatt\u00e9 T, Richter K. Paracetamol absorption from different sites in the human small intestine. Br J Clin Pharmacol. 1994;37(6):608\u201311. https:\/\/doi.org\/10.1111\/j.1365-2125.1994.tb04312.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"4043_CR21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1023\/a:1023481418576","volume":"20","author":"YY Chiu","year":"2003","unstructured":"Chiu YY, Higaki K, Neudeck BL, Barnett JL, Welage LS, Amidon GL. Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells. Pharm Res. 2003;20(5):749\u201356. https:\/\/doi.org\/10.1023\/a:1023481418576.","journal-title":"Pharm Res"},{"issue":"5","key":"4043_CR22","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/s0009-9236(96)90145-9","volume":"60","author":"A Lindahl","year":"1996","unstructured":"Lindahl A, Sandstr\u00f6m R, Ungell AL, Abrahamsson B, Knutson TW, Knutson L, et al. Jejunal permeability and hepatic extraction of fluvastatin in humans. Clin Pharmacol Ther. 1996;60(5):493\u2013503. https:\/\/doi.org\/10.1016\/s0009-9236(96)90145-9.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"4043_CR23","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1365-2125.1994.tb04309.x","volume":"37","author":"H Lennern\u00e4s","year":"1994","unstructured":"Lennern\u00e4s H, Ahrenstedt O, Ungell AL. Intestinal drug absorption during induced net water absorption in man; a mechanistic study using antipyrine, atenolol and enalaprilat. Br J Clin Pharmacol. 1994;37(6):589\u201396. https:\/\/doi.org\/10.1111\/j.1365-2125.1994.tb04309.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"4043_CR24","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1023\/a:1011916329863","volume":"15","author":"R Sandstr\u00f6m","year":"1998","unstructured":"Sandstr\u00f6m R, Karlsson A, Knutson L, Lennern\u00e4s H. Jejunal absorption and metabolism of R\/S-verapamil in humans. Pharm Res. 1998;15(6):856\u201362. https:\/\/doi.org\/10.1023\/a:1011916329863.","journal-title":"Pharm Res"},{"issue":"2","key":"4043_CR25","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1046\/j.1365-2125.2003.01722.x","volume":"55","author":"C Tannergren","year":"2003","unstructured":"Tannergren C, Knutson T, Knutson L, Lennern\u00e4s H. The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. Br J Clin Pharmacol. 2003;55(2):182\u201390. https:\/\/doi.org\/10.1046\/j.1365-2125.2003.01722.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"4043_CR26","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1365-2125.1993.tb05691.x","volume":"35","author":"H Lennern\u00e4s","year":"1993","unstructured":"Lennern\u00e4s H, Nilsson D, Aquilonius SM, Ahrenstedt O, Knutson L, Paalzow LK. The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. Br J Clin Pharmacol. 1993;35(3):243\u201350. https:\/\/doi.org\/10.1111\/j.1365-2125.1993.tb05691.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"4043_CR27","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/s0928-0987(02)00005-2","volume":"15","author":"H Lennern\u00e4s","year":"2002","unstructured":"Lennern\u00e4s H, Knutson L, Knutson T, Hussain A, Lesko L, Salmonson T, et al. The effect of amiloride on the in vivo effective permeability of amoxicillin in human jejunum: experience from a regional perfusion technique. Eur J Pharm Sci. 2002;15(3):271\u20137. https:\/\/doi.org\/10.1016\/s0928-0987(02)00005-2.","journal-title":"Eur J Pharm Sci"},{"issue":"25","key":"4043_CR28","doi-asserted-by":"publisher","first-page":"4939","DOI":"10.1021\/jm9810102","volume":"41","author":"S Winiwarter","year":"1998","unstructured":"Winiwarter S, Bonham NM, Ax F, Hallberg A, Lennern\u00e4s H, Karl\u00e9n A. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J Med Chem. 1998;41(25):4939\u201349. https:\/\/doi.org\/10.1021\/jm9810102.","journal-title":"J Med Chem"},{"issue":"7","key":"4043_CR29","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/j.2042-7158.1997.tb06084.x","volume":"49","author":"H Lennern\u00e4s","year":"1997","unstructured":"Lennern\u00e4s H. Human jejunal effective permeability and its correlation with preclinical drug absorption models. J Pharm Pharmacol. 1997;49(7):627\u201338. https:\/\/doi.org\/10.1111\/j.2042-7158.1997.tb06084.x.","journal-title":"J Pharm Pharmacol"},{"issue":"6","key":"4043_CR30","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1124\/dmd.31.6.805","volume":"31","author":"N Petri","year":"2003","unstructured":"Petri N, Tannergren C, Holst B, Mellon FA, Bao Y, Plumb GW, et al. Absorption\/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. Drug Metab Dispos. 2003;31(6):805\u201313. https:\/\/doi.org\/10.1124\/dmd.31.6.805.","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"4043_CR31","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1023\/a:1015888813741","volume":"9","author":"H Lennern\u00e4s","year":"1992","unstructured":"Lennern\u00e4s H, Ahrenstedt O, H\u00e4llgren R, Knutson L, Ryde M, Paalzow LK. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm Res. 1992;9(10):1243\u201351. https:\/\/doi.org\/10.1023\/a:1015888813741.","journal-title":"Pharm Res"},{"issue":"2","key":"4043_CR32","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1046\/j.1365-2125.1999.00999.x","volume":"48","author":"R Sandstr\u00f6m","year":"1999","unstructured":"Sandstr\u00f6m R, Knutson TW, Knutson L, Jansson B, Lennern\u00e4s H. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R\/S)-verapamil in humans. Br J Clin Pharmacol. 1999;48(2):180\u20139. https:\/\/doi.org\/10.1046\/j.1365-2125.1999.00999.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"4043_CR33","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1211\/0022357021778772","volume":"54","author":"H Lennern\u00e4s","year":"2002","unstructured":"Lennern\u00e4s H, Gjellan K, Hallgren R, Graffner C. The influence of caprate on rectal absorption of phenoxymethylpenicillin: experience from an in-vivo perfusion in humans. J Pharm Pharmacol. 2002;54(4):499\u2013508. https:\/\/doi.org\/10.1211\/0022357021778772.","journal-title":"J Pharm Pharmacol"},{"issue":"7","key":"4043_CR34","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1111\/j.2042-7158.1997.tb06092.x","volume":"49","author":"H Lennern\u00e4s","year":"1997","unstructured":"Lennern\u00e4s H, Lee ID, Fagerholm U, Amidon GL. A residence-time distribution analysis of the hydrodynamics within the intestine in man during a regional single-pass perfusion with Loc-I-Gut: in-vivo permeability estimation. J Pharm Pharmacol. 1997;49(7):682\u20136. https:\/\/doi.org\/10.1111\/j.2042-7158.1997.tb06092.x.","journal-title":"J Pharm Pharmacol"},{"issue":"3-4","key":"4043_CR35","first-page":"5","volume":"32","author":"ICRP","year":"2002","unstructured":"ICRP. Basic anatomical and physiological data for use in radiological protection: reference values. ICRP publication 89. Ann ICRP. 2002;32(3\u20134):5\u2013265.","journal-title":"Ann ICRP"},{"issue":"2","key":"4043_CR36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1365-2125.1985.tb02631.x","volume":"19","author":"J Sj\u00f6vall","year":"1985","unstructured":"Sj\u00f6vall J, Westerlund D, Alv\u00e1n G. Renal excretion of intravenously infused amoxycillin and ampicillin. Br J Clin Pharmacol. 1985;19(2):191\u2013201. https:\/\/doi.org\/10.1111\/j.1365-2125.1985.tb02631.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"4043_CR37","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1248\/bpb.b24-00012","volume":"47","author":"K Adachi","year":"2024","unstructured":"Adachi K, Ohyama K, Tanaka Y, Saito Y, Shimizu M, Yamazaki H. Modeled hepatic\/plasma exposures of fluvastatin prescribed alone in subjects with impaired cytochrome P450 2C9*3 as one of possible determinant factors likely associated with hepatic toxicity reported in a Japanese adverse event database. Biol Pharm Bull. 2024;47(3):635\u201340. https:\/\/doi.org\/10.1248\/bpb.b24-00012.","journal-title":"Biol Pharm Bull"},{"issue":"3","key":"4043_CR38","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2165\/00003088-198712030-00003","volume":"12","author":"D Debruyne","year":"1987","unstructured":"Debruyne D, de Hurault Ligny B, Ryckelynck JP, Albessard F, Moulin M. Clinical pharmacokinetics of ketoprofen after single intravenous administration as a bolus or infusion. Clin Pharmacokinet. 1987;12(3):214\u201321. https:\/\/doi.org\/10.2165\/00003088-198712030-00003.","journal-title":"Clin Pharmacokinet"},{"key":"4043_CR39","unstructured":"U.S. Food and Drug Administration. Orudis (ketoprofen) Capsules: Prescribing Information. 1986. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/019816s011lbl.pdf. Accessed 06 Jun 2025."},{"issue":"2","key":"4043_CR40","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1002\/cpt1974152178","volume":"15","author":"MR Kelly","year":"1974","unstructured":"Kelly MR, Cutler RE, Forrey AW, Kimpel BM. Pharmacokinetics of orally administered furosemide. Clin Pharmacol Ther. 1974;15(2):178\u201386.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"4043_CR41","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/bf01068079","volume":"9","author":"JG Wagner","year":"1981","unstructured":"Wagner JG, Popat KD, Das SK, Sakmar E, Movahhed H. Evidence of nonlinearity in digoxin pharmacokinetics. J Pharmacokinet Biopharm. 1981;9(2):147\u201366. https:\/\/doi.org\/10.1007\/bf01068079.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"8","key":"4043_CR42","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s40262-022-01145-y","volume":"61","author":"A Zamir","year":"2022","unstructured":"Zamir A, Hussain I, Ur Rehman A, Ashraf W, Imran I, Saeed H, et al. Clinical pharmacokinetics of metoprolol: a systematic review. Clin Pharmacokinet. 2022;61(8):1095\u2013114. https:\/\/doi.org\/10.1007\/s40262-022-01145-y.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"4043_CR43","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/BF01061407","volume":"2","author":"CG Reg\u00e5rdh","year":"1974","unstructured":"Reg\u00e5rdh CG, Borg KO, Johansson R, Johnsson G, Palmer L. Pharmacokinetic studies on the selective\u03b21-receptor antagonist metoprolol in man. J Pharmacokinet Biopharm. 1974;2(4):347\u201364. https:\/\/doi.org\/10.1007\/BF01061407.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"4","key":"4043_CR44","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1208\/s12248-017-0099-z","volume":"19","author":"RH Rose","year":"2017","unstructured":"Rose RH, Turner DB, Neuhoff S, Jamei M. Incorporation of the time-varying postprandial increase in splanchnic blood flow into a PBPK model to predict the effect of food on the pharmacokinetics of orally administered high-extraction drugs. AAPS J. 2017;19(4):1205\u201317. https:\/\/doi.org\/10.1208\/s12248-017-0099-z.","journal-title":"AAPS J"},{"issue":"1","key":"4043_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/j.1365-2125.1989.tb05334.x","volume":"27","author":"L Borgstr\u00f6m","year":"1989","unstructured":"Borgstr\u00f6m L, Nyberg L, J\u00f6nsson S, Lindberg C, Paulson J. Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate. Br J Clin Pharmacol. 1989;27(1):49\u201356. https:\/\/doi.org\/10.1111\/j.1365-2125.1989.tb05334.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"4043_CR46","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/bf00562061","volume":"16","author":"PJ Pentik\u00e4inen","year":"1979","unstructured":"Pentik\u00e4inen PJ, Neuvonen PJ, Penttil\u00e4 A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol. 1979;16(3):195\u2013202. https:\/\/doi.org\/10.1007\/bf00562061.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"4043_CR47","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/cpt1976204401","volume":"20","author":"WD Mason","year":"1976","unstructured":"Mason WD, Winer N. Pharmacokinetics of oxprenolol in normal subjects. Clin Pharmacol Ther. 1976;20(4):401\u201312. https:\/\/doi.org\/10.1002\/cpt1976204401.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"4043_CR48","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3109\/00498257409052112","volume":"4","author":"W Riess","year":"1974","unstructured":"Riess W, Huerzeler H, Raschdorf F. The metabolites of oxprenolol (Trasicor) in man. Xenobiotica. 1974;4(6):365\u201373. https:\/\/doi.org\/10.3109\/00498257409052112.","journal-title":"Xenobiotica"},{"issue":"2","key":"4043_CR49","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/bf03188723","volume":"7","author":"W Kirch","year":"1982","unstructured":"Kirch W, G\u00f6rg KG. Clinical pharmacokinetics of atenolol--a review. Eur J Drug Metab Pharmacokinet. 1982;7(2):81\u201391. https:\/\/doi.org\/10.1007\/bf03188723.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"4","key":"4043_CR50","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/clpt.1982.54","volume":"31","author":"RG McAllister Jr.","year":"1982","unstructured":"McAllister RG Jr., Kirsten EB. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther. 1982;31(4):418\u201326. https:\/\/doi.org\/10.1038\/clpt.1982.54.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"4043_CR51","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2165\/00003495-198938010-00003","volume":"38","author":"D McTavish","year":"1989","unstructured":"McTavish D, Sorkin EM. Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs. 1989;38(1):19\u201376. https:\/\/doi.org\/10.2165\/00003495-198938010-00003.","journal-title":"Drugs"},{"issue":"4","key":"4043_CR52","doi-asserted-by":"publisher","first-page":"306","DOI":"10.2165\/00003088-198106040-00005","volume":"6","author":"G Bodemar","year":"1981","unstructured":"Bodemar G, Norlander B, Walan A. Pharmacokinetics of cimetidine after single doses and during continuous treatment. Clin Pharmacokinet. 1981;6(4):306\u201315. https:\/\/doi.org\/10.2165\/00003088-198106040-00005.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"4043_CR53","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2165\/00003088-199427050-00002","volume":"27","author":"AK Scott","year":"1994","unstructured":"Scott AK. Sumatriptan clinical pharmacokinetics. Clin Pharmacokinet. 1994;27(5):337\u201344. https:\/\/doi.org\/10.2165\/00003088-199427050-00002.","journal-title":"Clin Pharmacokinet"},{"key":"4043_CR54","unstructured":"U.S. Food and Drug Administration. Exelon (Rivastigmine Tartrate) Capsules: Prescribing Information. 2000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2000\/20823_Exelon_biopharmr.pdf. Accessed 05 Jan 2026."},{"issue":"2","key":"4043_CR55","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S0022-3565(25)30593-8","volume":"198","author":"KC Kwan","year":"1976","unstructured":"Kwan KC, Foltz EL, Breault GO, Baer JE, Totaro JA. Pharmacokinetics of methyldopa in man. J Pharmacol Exp Ther. 1976;198(2):264\u201377.","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"4043_CR56","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejps.2010.03.009","volume":"40","author":"G Lappin","year":"2010","unstructured":"Lappin G, Shishikura Y, Jochemsen R, Weaver RJ, Gesson C, Houston B, et al. Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability. Eur J Pharm Sci. 2010;40(2):125\u201331. https:\/\/doi.org\/10.1016\/j.ejps.2010.03.009.","journal-title":"Eur J Pharm Sci"},{"key":"4043_CR57","unstructured":"U.S. Food and Drug Administration. Allegra (fexofenadine hydrochloride) Capsules: Prescribing Information. 1996. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2001\/20625lbl.pdf. Accessed 06 Jun 2025."},{"issue":"4","key":"4043_CR58","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/j.1365-2125.1995.tb04564.x","volume":"40","author":"J Roberts","year":"1995","unstructured":"Roberts J, Waller DG, O\u2019Shea N, Macklin BS, Renwick AG. The effect of selegiline on the peripheral pharmacokinetics of levodopa in young volunteers. Br J Clin Pharmacol. 1995;40(4):404\u20136. https:\/\/doi.org\/10.1111\/j.1365-2125.1995.tb04564.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"4043_CR59","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40262-017-0511-y","volume":"56","author":"A Mittur","year":"2017","unstructured":"Mittur A, Gupta S, Modi NB. Pharmacokinetics of Rytary(\u00ae), an extended-release capsule formulation of carbidopa-levodopa. Clin Pharmacokinet. 2017;56(9):999\u20131014. https:\/\/doi.org\/10.1007\/s40262-017-0511-y.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"4043_CR60","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/bdd.2510100407","volume":"10","author":"B Beermann","year":"1989","unstructured":"Beermann B, Till AE, Gomez HJ, Hichens M, Bolognese JA, Junggren I. Pharmacokinetics of lisinopril (IV\/PO) in healthy volunteers. Biopharm Drug Dispos. 1989;10(4):397\u2013409. https:\/\/doi.org\/10.1002\/bdd.2510100407.","journal-title":"Biopharm Drug Dispos"},{"issue":"3","key":"4043_CR61","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/bcp.14492","volume":"87","author":"F Xie","year":"2021","unstructured":"Xie F, Van Bocxlaer J, Vermeulen A. Physiologically based pharmacokinetic modelling of lisinopril in children: a case story of angiotensin converting enzyme inhibitors. Br J Clin Pharmacol. 2021;87(3):1203\u201314. https:\/\/doi.org\/10.1111\/bcp.14492.","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"4043_CR62","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/clpt.1982.109","volume":"31","author":"NP Chau","year":"1982","unstructured":"Chau NP, Zech PY, Pozet N, Hadj-Aissa A. Ranitidine kinetics in normal subjects. Clin Pharmacol Ther. 1982;31(6):770\u20134. https:\/\/doi.org\/10.1038\/clpt.1982.109.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"4043_CR63","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/bf01642232","volume":"2","author":"C Regamey","year":"1974","unstructured":"Regamey C, Libke RD, Clarke JT, Kirby WM. Pharmacokinetics of parenteral sodium cephalexin in comparison with cephalothin and cefazolin. Infection. 1974;2(3):132\u20136. https:\/\/doi.org\/10.1007\/bf01642232.","journal-title":"Infection"},{"key":"4043_CR64","unstructured":"U.S. Food and Drug Administration. Acetaminophen Injection: Prescribing Information. 1951. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/204767s000lbl.pdf. Accessed 06 Jun 2025."},{"issue":"2","key":"4043_CR65","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00003088-198207020-00001","volume":"7","author":"JA Forrest","year":"1982","unstructured":"Forrest JA, Clements JA, Prescott LF. Clinical pharmacokinetics of paracetamol. Clin Pharmacokinet. 1982;7(2):93\u2013107. https:\/\/doi.org\/10.2165\/00003088-198207020-00001.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"4043_CR66","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/0009-9236(95)90032-2","volume":"57","author":"MP Ducharme","year":"1995","unstructured":"Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther. 1995;57(5):485\u201391. https:\/\/doi.org\/10.1016\/0009-9236(95)90032-2.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"4043_CR67","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/j.1552-4604.1987.tb02193.x","volume":"27","author":"RJ Ptachcinski","year":"1987","unstructured":"Ptachcinski RJ, Venkataramanan R, Burckart GJ, Gray JA, Van Thiel DH, Sanghvi A, et al. Cyclosporine kinetics in healthy volunteers. J Clin Pharmacol. 1987;27(3):243\u20138. https:\/\/doi.org\/10.1002\/j.1552-4604.1987.tb02193.x.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"4043_CR68","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/bf00542332","volume":"21","author":"M Danhof","year":"1982","unstructured":"Danhof M, van Zuilen A, Boeijinga JK, Breimer DD. Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time. Eur J Clin Pharmacol. 1982;21(5):433\u201341. https:\/\/doi.org\/10.1007\/bf00542332.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"4043_CR69","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/j.1365-2125.1982.tb04967.x","volume":"14","author":"GT Tucker","year":"1982","unstructured":"Tucker GT, Bax ND, Lennard MS, Crewe K, Woods HF. Lack of effect of atenolol on antipyrine clearance. Br J Clin Pharmacol. 1982;14(5):743\u20134. https:\/\/doi.org\/10.1111\/j.1365-2125.1982.tb04967.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"4043_CR70","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1111\/j.1528-1157.1990.tb05384.x","volume":"31","author":"A G\u00e9rardin","year":"1990","unstructured":"G\u00e9rardin A, Dubois JP, Moppert J, Geller L. Absolute bioavailability of carbamazepine after oral administration of a 2% syrup. Epilepsia. 1990;31(3):334\u20138. https:\/\/doi.org\/10.1111\/j.1528-1157.1990.tb05384.x.","journal-title":"Epilepsia"},{"key":"4043_CR71","unstructured":"U.S. Food and Drug Administration. EQUETRO (carbamazepine) extended-release capsules: Prescribing Information. 1968. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021710s11s012lbl.pdf. Accessed 06 Jun 2025."},{"key":"4043_CR72","doi-asserted-by":"publisher","first-page":"105617","DOI":"10.1016\/j.ejps.2020.105617","volume":"157","author":"A Effinger","year":"2021","unstructured":"Effinger A, O\u2019Driscoll CM, McAllister M, Fotaki N. Predicting budesonide performance in healthy subjects and patients with Crohn\u2019s disease using biorelevant in vitro dissolution testing and PBPK modeling. Eur J Pharm Sci. 2021;157:105617. https:\/\/doi.org\/10.1016\/j.ejps.2020.105617.","journal-title":"Eur J Pharm Sci"},{"key":"4043_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15092237","author":"C Han","year":"2023","unstructured":"Han C, Sun T, Chirumamilla SK, Bois FY, Xu M, Rostami-Hodjegan A. Understanding discordance between in vitro dissolution, local gut and systemic bioequivalence of budesonide in healthy and Crohn\u2019s disease patients through PBPK modeling. Pharmaceutics. 2023. https:\/\/doi.org\/10.3390\/pharmaceutics15092237.","journal-title":"Pharmaceutics"},{"issue":"6","key":"4043_CR74","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/bdd.2510070605","volume":"7","author":"E Cid","year":"1986","unstructured":"Cid E, Mella F, Lucchini L, C\u00e1rcamo M, Monasterio J. Plasma concentrations and bioavailability of propranolol by oral, rectal, and intravenous administration in man. Biopharm Drug Dispos. 1986;7(6):559\u201366. https:\/\/doi.org\/10.1002\/bdd.2510070605.","journal-title":"Biopharm Drug Dispos"},{"issue":"4","key":"4043_CR75","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1177\/0269881108093841","volume":"23","author":"DR Jasinski","year":"2009","unstructured":"Jasinski DR, Krishnan S. Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers. J Psychopharmacol. 2009;23(4):410\u20138. https:\/\/doi.org\/10.1177\/0269881108093841.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"4043_CR76","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1517\/17425225.3.4.469","volume":"3","author":"S Hurst","year":"2007","unstructured":"Hurst S, Loi CM, Brodfuehrer J, El-Kattan A. Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opin Drug Metab Toxicol. 2007;3(4):469\u201389. https:\/\/doi.org\/10.1517\/17425225.3.4.469.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"4043_CR77","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5599\/admet.1.2.3","volume":"1","author":"K Tak\u00e1cs-Nov\u00e1k","year":"2013","unstructured":"Tak\u00e1cs-Nov\u00e1k K, De\u00e1k K, B\u00e9ni S, V\u00f6lgyi G. Physico-chemical profiling of the ACE-inhibitor lisinopril: acid-base properties. ADMET DMPK. 2013;1(2):6\u201316.","journal-title":"ADMET DMPK"},{"key":"4043_CR78","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejpb.2019.06.011","volume":"142","author":"D Dahlgren","year":"2019","unstructured":"Dahlgren D, Roos C, Peters K, Lundqvist A, Tannergren C, Sj\u00f6gren E, et al. Evaluation of drug permeability calculation based on luminal disappearance and plasma appearance in the rat single-pass intestinal perfusion model. Eur J Pharm Biopharm. 2019;142:31\u20137. https:\/\/doi.org\/10.1016\/j.ejpb.2019.06.011.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"4043_CR79","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/0005-2736(95)00030-7","volume":"1236","author":"PW Swaan","year":"1995","unstructured":"Swaan PW, Stehouwer MC, Tukker JJ. Molecular mechanism for the relative binding affinity to the intestinal peptide carrier. Comparison of three ACE-inhibitors: enalapril, enalaprilat, and lisinopril. Biochim Biophys Acta. 1995;1236(1):31\u20138. https:\/\/doi.org\/10.1016\/0005-2736(95)00030-7.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"4043_CR80","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/s0378-5173(99)00147-7","volume":"186","author":"LX Yu","year":"1999","unstructured":"Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm. 1999;186(2):119\u201325. https:\/\/doi.org\/10.1016\/s0378-5173(99)00147-7.","journal-title":"Int J Pharm"},{"key":"4043_CR81","unstructured":"U.S. Food and Drug Administration. LASIX\u00ae (furosemide) tablets 20, 40, and 80 mg: Prescibing Information. 2010. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/016273s061lbl.pdf. Accessed 12 Jan 2026."},{"issue":"10","key":"4043_CR82","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1023\/a:1020483911355","volume":"19","author":"D Sun","year":"2002","unstructured":"Sun D, Lennernas H, Welage LS, Barnett JL, Landowski CP, Foster D, et al. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res. 2002;19(10):1400\u201316. https:\/\/doi.org\/10.1023\/a:1020483911355.","journal-title":"Pharm Res"},{"issue":"3","key":"4043_CR83","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1067\/mcp.2003.27","volume":"73","author":"S Drescher","year":"2003","unstructured":"Drescher S, Glaeser H, M\u00fcrdter T, Hitzl M, Eichelbaum M, Fromm MF. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther. 2003;73(3):223\u201331. https:\/\/doi.org\/10.1067\/mcp.2003.27.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"4043_CR84","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/cpt.317","volume":"99","author":"J Matthaei","year":"2016","unstructured":"Matthaei J, Kuron D, Faltraco F, Knoch T, Dos Santos Pereira JN, Abu Abed M, et al. OCT1 mediates hepatic uptake of sumatriptan and loss-of-function OCT1 polymorphisms affect sumatriptan pharmacokinetics. Clin Pharmacol Ther. 2016;99(6):633\u201341. https:\/\/doi.org\/10.1002\/cpt.317.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"4043_CR85","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/00054725-200409000-00012","volume":"10","author":"K Dilger","year":"2004","unstructured":"Dilger K, Schwab M, Fromm MF. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm Bowel Dis. 2004;10(5):578\u201383. https:\/\/doi.org\/10.1097\/00054725-200409000-00012.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"4043_CR86","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1080\/17425255.2018.1459565","volume":"14","author":"Y Akamine","year":"2018","unstructured":"Akamine Y, Miura M. An update on the clinical pharmacokinetics of fexofenadine enantiomers. Expert Opin Drug Metab Toxicol. 2018;14(4):429\u201334. https:\/\/doi.org\/10.1080\/17425255.2018.1459565.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4043_CR87","doi-asserted-by":"publisher","first-page":"317","DOI":"10.2147\/ndt.s9749","volume":"6","author":"M Pennick","year":"2010","unstructured":"Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317\u201327. https:\/\/doi.org\/10.2147\/ndt.s9749.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"9","key":"4043_CR88","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1016\/j.xphs.2017.04.078","volume":"106","author":"X Liang","year":"2017","unstructured":"Liang X, Giacomini KM. Transporters involved in Metformin pharmacokinetics and treatment response. J Pharm Sci. 2017;106(9):2245\u201350. https:\/\/doi.org\/10.1016\/j.xphs.2017.04.078.","journal-title":"J Pharm Sci"},{"issue":"6","key":"4043_CR89","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/00003088-199120060-00001","volume":"20","author":"TM Ludden","year":"1991","unstructured":"Ludden TM. Nonlinear pharmacokinetics: clinical implications. Clin Pharmacokinet. 1991;20(6):429\u201346. https:\/\/doi.org\/10.2165\/00003088-199120060-00001.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"4043_CR90","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s11030-021-10186-7","volume":"25","author":"H Mamada","year":"2021","unstructured":"Mamada H, Iwamoto K, Nomura Y, Uesawa Y. Predicting blood-to-plasma concentration ratios of drugs from chemical structures and volumes of distribution in humans. Mol Divers. 2021;25(3):1261\u201370. https:\/\/doi.org\/10.1007\/s11030-021-10186-7.","journal-title":"Mol Divers"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04043-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04043-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04043-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:54:03Z","timestamp":1778867643000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04043-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4043"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04043-1","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}